Enovis (ENOV) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MaxCyte (MXCT) has outperformed Enovis (ENOV) over the past year, losing 40.0% versus a loss of 45.2%. Over five years, ENOV leads with a -80.0% price change compared with -90.8% for MXCT. Enovis is the larger company by market cap ($1.02 billion vs $104.2 million), about 9.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | MXCT |
|---|---|---|
| Share price | $17.69 | $1.01 |
| Market cap | $1.02B | $104.24M |
| 1-day change | +1.49% | -0.98% |
| YTD return | -34.57% | -34.19% |
| 1-year return | -45.15% | -40.00% |
| 5-year return | -79.99% | -90.75% |
| Forward P/E | 4.93 | — |
| EPS (TTM) | $-19.23 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.28 | $1.87 |
| 52-week low | $16.70 | $0.643 |
| Distance from 52-week high | -48.40% | -45.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +112.44% | +306.93% |
| Average volume | 1.46M | 668.82K |
| Shares outstanding | 57.67M | 103.21M |
| Employees | 7,802 | 91 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Enovis is about 9.8 times larger than MaxCyte by market value ($1.02B vs $104.24M).
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
ENOV vs MXCT FAQ
Which is bigger, Enovis or MaxCyte?
Enovis (ENOV) is larger, with a market capitalization of $1.02B compared with $104.24M for MaxCyte (MXCT).
Which stock has performed better over the past year, ENOV or MXCT?
MXCT returned -40.00% over the past 12 months, compared with -45.15% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Are Enovis and MaxCyte in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Enovis and Biotechnology: Commercial Physical & Biological Resarch for MaxCyte.